An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine
Figure 3
Acute effects of the SGA drugs lurasidone and olanzapine in adult female rats in the hyperinsulinemic-euglycemic clamp.
Animals (n = 6–10 per group) were fasted overnight and subjected to the hyperinsulinemic-euglycemic clamp. After animals reached euglycemia (three consecutive blood glucose readings of 6.0±0.4 mmol/L), rats were treated with vehicle, lurasidone (0.2, 0.8 or 2.0 mg/kg, s.c) or olanzapine (1.5 or 15 mg/kg, s.c.) in a volume 1 ml/kg. Glucose levels were recorded every 10 minutes and the glucose infusion rate was adjusted as needed. Glucose infusion rates for each treatment group are presented as change in glucose infusion rate from euglycemia. Values represent group means ± SEM. *indicates different from vehicle-treated animals, p<0.05; **indicates different from vehicle-treated animals, p<0.01.